Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis

被引：1

作者：

De Felice, Francesca ^{[1
]}

Bossi, Paolo ^{[2
]}

机构：

[1] Sapienza Univ Rome, Dept Radiol, Radiat Oncol, Policlin Umberto I, Viale Regina Elena 326, I-00161 Rome, Italy

[2] Univ Brescia, Dept Med & Surg Specialties, Med Oncol Unit, Radiol Sci & Publ Hlth Med Oncol, I-25123 Brescia, Italy

来源：

ORAL ONCOLOGY | 2023年 / 137卷

关键词：

Immunotherapy; First line; Chemotherapy; Head neck cancer; Metastasis;

D O I：

10.1016/j.oraloncology.2022.106275

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 5 条

[1] Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 "PembroRad" randomized trial [J].

Bourhis, J. ;

Sire, C. ;

Tao, Y. ;

Martin, L. ;

Alfonsi, M. ;

Prevost, J. B. ;

Rives, M. ;

Lafond, C. ;

Tourani, J. M. ;

Biau, J. ;

Geoffrois, L. ;

Coutte, A. ;

Liem, X. ;

Vauleon, E. ;

Drouet, F. ;

Pechery, A. ;

Guigay, J. ;

Wanneveich, M. ;

Auperin, A. ;

Sun, X. .

ANNALS OF ONCOLOGY, 2020, 31 :S1168-S1168

[2]

Harrington KJ, 2022, J CLIN ONCOL

[3]

Lee NY, 2021, LANCET ONCOL, V22, P450, DOI 10.1016/S1470-2045(20)30737-3

[4]

Machiels JP, 2022, ESMO C 2022

[5] Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age [J].

Saba, Nabil F. ;

Blumenschein, George, Jr. ;

Guigay, Joel ;

Licitra, Lisa ;

Fayette, Jerome ;

Harrington, Kevin J. ;

Kiyota, Naomi ;

Gillison, Maura L. ;

Ferris, Robert L. ;

Jayaprakash, Vijayvel ;

Li, Li ;

Brossart, Peter .

ORAL ONCOLOGY, 2019, 96 :7-14

← 1 →